Compass Pathways vs Degron Therapeutics
Compass Pathways vs Degron Therapeutics, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Compass Pathways is on 57/100 and Degron Therapeutics on 62/100.
Where each one leads
Compass Pathways
- agent readiness: 48/100 against 27/100
- domain rating: 65/100 against 25/100
- headcount: 241 against 24
- funding raised: $294M against $40.0M
- LinkedIn following: 39,951 against 1,380
Degron Therapeutics
- our overall score: 62/100 against 57/100
At a glance
| Measure | Compass Pathways | Degron Therapeutics |
|---|---|---|
| What it is | Accelerating patient access to evidence-based innovation in mental health. | Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. |
| Category | Biotechnology, Healthcare, Mental Health, Pharmaceuticals | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare |
| Sells toBusiness model | B2B2C | B2B |
| Offering | Services | Platform |
| Founded | 2018 | 2020 |
| Headquarters | London, United Kingdom | San Diego, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Compass Pathways | Degron Therapeutics |
|---|---|---|
| Employees | 241 | 24 |
| Total funding | $294M | $40.0M |
| Latest round | IPO | Series A Extension |
| Valuation | $1.1B | $1.1B |
| LinkedIn followers | 39,951 | 1,380 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Compass Pathways | Degron Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 57/100 | 62/100 |
| Traction | 60/100 | Not published |
| Team | 30/100 | 24/100 |
| Search visibility | 31/100 | 57/100 |
| Quality | 68/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | D (48/100) | F (27/100) |
| Domain ratingLink authority, 0-100 | 65/100 | 25/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Compass Pathways | Degron Therapeutics |
|---|---|---|
| Hosting | AWS | Self Managed |
| CDN | Cloudflare | Not detected |
| Frameworks | Next.js, Tailwind CSS | Not detected |
| Analytics | Google Tag Manager | Not detected |
Compass Pathways vs Degron Therapeutics: common questions
Which is better, Compass Pathways or Degron Therapeutics?
On our 0-100 score Degron Therapeutics rates higher (62/100 against 57/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do Compass Pathways and Degron Therapeutics compare on the numbers?
Compass Pathways leads on agent readiness (48/100 against 27/100), domain rating (65/100 against 25/100), headcount (241 against 24), funding raised ($294M against $40.0M), LinkedIn following (39,951 against 1,380). Degron Therapeutics leads on our overall score (62/100 against 57/100).
Read the full Compass Pathways review and pricing or the Degron Therapeutics review and pricing. You can also browse other Compass Pathways alternatives we track.